Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christine Hunter

Obstetrics & Gynecology Summerville, SC Medical Doctor

NPI 1093789976 CMS profile 4659

83 Springview Ln, Summerville, SC 29485

Open in the dashboard

General payments

$6,367

333 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$4

4 holdings reported · through program year 2025

Research they led as principal investigator

$96,078 paid to institutions, not to them · program years 2020–2023

Through program year 2025, Christine Hunter of Summerville, SC is reported in the CMS Open Payments database as having received $6,367 across 333 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $96,078 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $4 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,074 43
2024 General $1,092 56
2023 General $1,186 67
2022 General $1,813 91
2021 General $477 30
2020 General $435 27
2019 General $290 19
2024 Ownership $1 1
2023 Ownership $1 1
2022 Ownership $1 1
2021 Ownership $1 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine Hunter
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Christine Hunter were reported at $1,074. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Christine Hunter Obstetrics & Gynecology median Middle half National median
2019 $290 $172 $62–$391 $163
2020 $435 $94 $36–$222 $114
2021 $477 $136 $42–$369 $132
2022 $1,813 $160 $50–$433 $149
2023 $1,186 $169 $56–$423 $160
2024 $1,092 $152 $50–$371 $164
2025 $1,074 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,267 89 payments
  2. Sumitomo Pharma America, Inc. $1,110 45 payments
  3. Hologic, LLC $482 20 payments
  4. Exeltis, USA Inc. $326 20 payments
  5. Pfizer Inc. $307 13 payments
  6. Mayne Pharma Inc. $240 13 payments
  7. Myovant Sciences Inc. $209 14 payments
  8. Organon LLC $204 13 payments
  9. Astellas Pharma US Inc $187 9 payments
  10. Shield Therapeutics Inc $186 10 payments
  11. Other $1,850 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,367 333 payments
Products named General payments · program years 2019–2025
  1. MYFEMBREE Hormone Therapy $997 51 payments
  2. ORILISSA $732 54 payments
  3. LO LOESTRIN FE $670 48 payments
  4. ORIAHNN $477 33 payments
  5. MYFEMBREE Womens Health $323 8 payments
  6. PREMARIN $308 19 payments
  7. Aptima $257 9 payments
  8. THINPREP 2000 PROCESSOR $223 7 payments
  9. LILETTA $205 14 payments
  10. NEXPLANON $188 12 payments
  11. Other $3,916 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

214

Median for Obstetrics & Gynecology: 65

Drug cost

$9,889

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

50.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 59 $3,935
Valacyclovir Valacyclovir Hcl Brand 72 $2,832
Estradiol (Twice Weekly) Estradiol Brand 17 $1,331
Progesterone Progesterone, Micronized Brand 20 $522
Terconazole Generic 17 $482
Clobetasol Propionate Generic 18 $444
Norethindrone Generic 11 $342

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$26,473

Medicare's payments for the services billed

Medicare patients

152

Average age 70

Services billed

596

152 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 46%
Diabetes 24%
Chronic kidney disease 20%
Osteoporosis 20%
Depression 18%
Cancer 13%
COPD 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $390
  • PFIZER INC. $6
$396 — —
SLYND
  • Exeltis, USA Inc. $95
$95 — —
Veozah
  • Astellas Pharma US Inc $50
$50 — —
ABRYSVO
  • PFIZER INC. $12
$12 — —
LO LOESTRIN FE
  • AbbVie, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record